Clinical Trial Update: Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL [Phase 1, Phase 2]

View source ↗

Summary

A two-phase early-stage trial evaluated IPH2201 (monalizumab) in combination with ibrutinib for chronic lymphocytic leukemia; the study is terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IPH2201
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Innate Pharma | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-12-17